Global Intravenous Iron Drugs Market By Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, and Others), By Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, and Others), By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030

Report ID :AMI-1143 | Category : Healthcare | Published Date : April, 2022 | Pages : 402 | Format :PDF

Industry Trends

Iron is involved in neurotransmitter production, myoglobin formation, collagen growth, and immune system activity, in addition to heme synthesis and energy metabolism. Iron is a necessary element. Anaemia has become one of the most frequent blood illnesses in recent years due to an increase in its incidence. According to the National Heart, Lung, and Blood Institute, anaemia affects around 3 million people in the United States. The rising prevalence of target diseases such as rheumatoid arthritis, autoimmune diseases, renal diseases, cancer, liver disorders, thyroid diseases, and inflammatory bowel diseases, amongst others, is driving the intravenous iron drugs market demand. The most prevalent causes of anaemia include iron and vitamin deficiencies, as well as plastic, hemolytic, and sickle cell anaemia. Iron, vitamin A, vitamin B12, and folate deficits are the most common causes of anaemia. Infectious disorders such as tuberculosis, parasitic infections, malaria, and HIV are the leading causes of anaemia in people all over the world.

Oral iron supplements are indicated to help counteract this problem and keep the body's iron levels steady. Oral administrations, on the other hand, may not be helpful in sustaining iron levels in the body under certain conditions. When IV iron therapy is needed, a syringe is used to inject iron directly into the body through a vein. IV iron treatment is only used in very specific situations. The rising frequency of iron deficiency, the rising number of chronic renal disease patients requiring dialysis, and the rising number of diabetics are all driving the intravenous iron drugs market forward. An increase in the prevalence of iron deficiency anaemia in gynaecology, oncology, and gastroenterology, as well as noncompliance with oral treatment and the availability of accurate, quick, and approachable IV iron doses in these domains, are driving the demand for intravenous iron therapies.

In the near future, the intravenous iron drugs market is projected to be limited by a lengthy approval process, severe regulations, drug side effects, the availability of nutraceutical options to avoid iron deficiency, and product cost. Despite the detrimental impact of the COVID-19 outbreak on intravenous iron medication manufacturing and supply, the business has grown as a consequence of strong efforts by enterprises and the government to meet customer demand. The global intravenous iron drugs market was worth USD 2.2 billion in 2020, and between 2022 to 2030, it is predicted to grow at an annual pace of 9.2 percent.

Global Intravenous Iron Drugs Market Revenue & Forecast, (US$ Million), 2015 – 2030

Product Outlook

The global intravenous iron drugs market is divided into four groups based on the product: iron Dextran, iron Sucrose, ferric Carboxymaltose, and Others. Because of its expanded applicability, improved performance, and lower cost, the Ferric Carboxymaltose (FCM) category dominated the market for intravenous iron therapies in 2021 with a revenue share of 46.9%. This dominant position is projected to be maintained over the forecast period. Over the projection period, the launch of novel iron medication formulations is expected to create significant growth in the others category. Ferumoxytol medicines can be given quickly and in large dosages without the requirement for a test dose, giving the company a huge profit margin. As a result, the others segment is expected to increase at the quickest rate over the projection period.

Application Outlook

Chronic kidney disease, inflammatory bowel disease, cancer, and others are the four application areas that make up the global intravenous iron drugs market. According to research, intravenous iron medicines will account for its 30.8 percent of total revenue from the chronic renal illness category in 2021. Increased prevalence of chronic kidney disease (CKD) and the high incidence of IDA among CKD patients are few drivers of the market. In those with chronic renal disease, IDA is a common complication (CKD). Although it is uncommon in the early stages of renal failure, it does develop as the disease progresses and kidney function declines. As the number of people with chronic kidney disease (CKD) rises, the number of patients with IDA rises as well. For people with chronic kidney disease (CKD), whether or not they are on dialysis, an injectable iron product is the conventional treatment.

Region Outlook

North America is predicted to dominate the intravenous iron drugs market in 2021, accounting for 39.9% of total market revenue. This is due to increased approvals and the introduction of new intravenous pharmaceuticals in the United States. The higher prevalence of cancer, chronic kidney illness, and gastrointestinal ailments in the population is another factor contributing to the region's dominance. Over the anticipated time period, the market in Asia Pacific is expected to develop at the fastest rate. This is due to significant firms' geographic expansion into Asia Pacific countries, as well as the region's growing healthcare infrastructure and government efforts.

Competitive Environment

Due to the presence of multiple global businesses in the industry, the market for intravenous iron medications is quite competitive. According to the business, Daiichi Sankyo Company, Ltd. and Vifor Pharma Management Ltd. would generate great majority of the market revenue in 2021. To get a larger portion of the market, they use a number of growth techniques, such as new product development and global expansion. Some of the key players operating in the global intravenous iron drugs market are:

AbbVie, Inc.
Actavis Inc.
AMAG Pharmaceuticals, Inc.
American Regent, Inc.
Daiichi Sankyo Vietnam Company Limited
Fresenius Medical Care AG & Co. KGaA
Galenica Ltd.
Luitpold Pharmaceuticals, Inc.
Pharmacosmos A/S
Rockwell Medical Technologies, Inc.
Sanofi
Vifor Pharma Ltd.
Other Market Participants

Click on image to enlarge

Global Intravenous Iron Drugs Market:

By Product

Iron Dextran
Iron Sucrose
Ferric Carboxymaltose
Others

By Application

Chronic Kidney Disease
Inflammatory Bowel Disease
Cancer
Others

By Region

North America
- US
- Canada
- Mexico
- Rest of North America
Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
  - Denmark
  - Finland
  - Iceland
  - Sweden
  - Norway
- Benelux Union
  - Belgium
  - The Netherlands
  - Luxembourg
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
  - Indonesia
  - Thailand
  - Malaysia
  - Singapore
  - Rest of Southeast Asia
- Rest of Asia Pacific
Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina

Rest of Latin America

Table of Contents

1. Market Scope

1.1. Market Segmentation

1.2. Years Considered

1.2.1. Historic Years: 2015 - 2020

1.2.2. Base Year: 2021

1.2.3. Forecast Years: 2022 – 2030

2. Key Target Audiences

3. Research Methodology

3.1. Primary Research

3.1.1. Research Questionnaire

3.1.2. Global Percentage Breakdown

3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)

3.2. Secondary Research

3.2.1. Paid Databases

3.2.2. Secondary Sources

3.3. Market Size Estimates

3.3.1. Top-Down Approach

3.3.2. Bottom-Up Approach

3.4. Data Triangulation Methodology

3.5. Research Assumptions

4. Recommendations and Insights from AMI’s Perspective**

5. Holistic Overview of Intravenous Iron Drugs Market

6. Market Synopsis: Intravenous Iron Drugs Market

7. Intravenous Iron Drugs Market Analysis: Qualitative Perspective

7.1. Introduction

7.1.1. Product Definition

7.1.2. Industry Development

7.2. Market Dynamics

7.2.1. Drivers

7.2.2. Restraints

7.2.3. Opportunities

7.2.4. Challenges

7.3. Trends in Intravenous Iron Drugs Market

7.4. Market Determinants Radar Chart

7.5. Macro-Economic and Micro-Economic Indicators: Intravenous Iron Drugs Market

7.6. Porter’s Five Force Analysis

7.7. Impact of Covid-19 on Intravenous Iron Drugs Market

8. Global Intravenous Iron Drugs Market Analysis and Forecasts, 2022 – 2030

8.1. Overview

8.1.1. Global Intravenous Iron Drugs Market Revenue (US$ Mn)

8.2. Global Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

8.2.1. Iron Dextran

8.2.1.1. Definition

8.2.1.2. Market Estimation and Penetration, 2015 - 2021

8.2.1.3. Market Forecast, 2022 - 2030

8.2.1.4. Compound Annual Growth Rate (CAGR)

8.2.1.5. Regional Bifurcation

8.2.1.5.1. North America

8.2.1.5.1.1. Market Estimation, 2015 - 2021

8.2.1.5.1.2. Market Forecast, 2022 - 2030

8.2.1.5.2. Europe

8.2.1.5.2.1. Market Estimation, 2015 - 2021

8.2.1.5.2.2. Market Forecast, 2022 - 2030

8.2.1.5.3. Asia Pacific

8.2.1.5.3.1. Market Estimation, 2015 - 2021

8.2.1.5.3.2. Market Forecast, 2022 - 2030

8.2.1.5.4. Middle East and Africa

8.2.1.5.4.1. Market Estimation, 2015 - 2021

8.2.1.5.4.2. Market Forecast, 2022 - 2030

8.2.1.5.5. Latin America

8.2.1.5.5.1. Market Estimation, 2015 - 2021

8.2.1.5.5.2. Market Forecast, 2022 - 2030

8.2.2. Iron Sucrose

8.2.2.1. Definition

8.2.2.2. Market Estimation and Penetration, 2015 - 2021

8.2.2.3. Market Forecast, 2022 - 2030

8.2.2.4. Compound Annual Growth Rate (CAGR)

8.2.2.5. Regional Bifurcation

8.2.2.5.1. North America

8.2.2.5.1.1. Market Estimation, 2015 - 2021

8.2.2.5.1.2. Market Forecast, 2022 - 2030

8.2.2.5.2. Europe

8.2.2.5.2.1. Market Estimation, 2015 - 2021

8.2.2.5.2.2. Market Forecast, 2022 - 2030

8.2.2.5.3. Asia Pacific

8.2.2.5.3.1. Market Estimation, 2015 - 2021

8.2.2.5.3.2. Market Forecast, 2022 - 2030

8.2.2.5.4. Middle East and Africa

8.2.2.5.4.1. Market Estimation, 2015 - 2021

8.2.2.5.4.2. Market Forecast, 2022 - 2030

8.2.2.5.5. Latin America

8.2.2.5.5.1. Market Estimation, 2015 - 2021

8.2.2.5.5.2. Market Forecast, 2022 - 2030

8.2.3. Ferric Carboxymaltose

8.2.3.1. Definition

8.2.3.2. Market Estimation and Penetration, 2015 - 2021

8.2.3.3. Market Forecast, 2022 - 2030

8.2.3.4. Compound Annual Growth Rate (CAGR)

8.2.3.5. Regional Bifurcation

8.2.3.5.1. North America

8.2.3.5.1.1. Market Estimation, 2015 - 2021

8.2.3.5.1.2. Market Forecast, 2022 - 2030

8.2.3.5.2. Europe

8.2.3.5.2.1. Market Estimation, 2015 - 2021

8.2.3.5.2.2. Market Forecast, 2022 - 2030

8.2.3.5.3. Asia Pacific

8.2.3.5.3.1. Market Estimation, 2015 - 2021

8.2.3.5.3.2. Market Forecast, 2022 - 2030

8.2.3.5.4. Middle East and Africa

8.2.3.5.4.1. Market Estimation, 2015 - 2021

8.2.3.5.4.2. Market Forecast, 2022 - 2030

8.2.3.5.5. Latin America

8.2.3.5.5.1. Market Estimation, 2015 - 2021

8.2.3.5.5.2. Market Forecast, 2022 - 2030

8.2.4. Others

8.2.4.1. Definition

8.2.4.2. Market Estimation and Penetration, 2015 - 2021

8.2.4.3. Market Forecast, 2022 - 2030

8.2.4.4. Compound Annual Growth Rate (CAGR)

8.2.4.5. Regional Bifurcation

8.2.4.5.1. North America

8.2.4.5.1.1. Market Estimation, 2015 - 2021

8.2.4.5.1.2. Market Forecast, 2022 - 2030

8.2.4.5.2. Europe

8.2.4.5.2.1. Market Estimation, 2015 - 2021

8.2.4.5.2.2. Market Forecast, 2022 - 2030

8.2.4.5.3. Asia Pacific

8.2.4.5.3.1. Market Estimation, 2015 - 2021

8.2.4.5.3.2. Market Forecast, 2022 - 2030

8.2.4.5.4. Middle East and Africa

8.2.4.5.4.1. Market Estimation, 2015 - 2021

8.2.4.5.4.2. Market Forecast, 2022 - 2030

8.2.4.5.5. Latin America

8.2.4.5.5.1. Market Estimation, 2015 - 2021

8.2.4.5.5.2. Market Forecast, 2022 - 2030

8.3. Key Segment for Channeling Investments

8.3.1. By Product

9. Global Intravenous Iron Drugs Market Analysis and Forecasts, 2022 – 2030

9.1. Overview

9.2. Global Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

9.2.1. Chronic Kidney Disease

9.2.1.1. Definition

9.2.1.2. Market Estimation and Penetration, 2015 - 2021

9.2.1.3. Market Forecast, 2022 - 2030

9.2.1.4. Compound Annual Growth Rate (CAGR)

9.2.1.5. Regional Bifurcation

9.2.1.5.1. North America

9.2.1.5.1.1. Market Estimation, 2015 - 2021

9.2.1.5.1.2. Market Forecast, 2022 - 2030

9.2.1.5.2. Europe

9.2.1.5.2.1. Market Estimation, 2015 - 2021

9.2.1.5.2.2. Market Forecast, 2022 - 2030

9.2.1.5.3. Asia Pacific

9.2.1.5.3.1. Market Estimation, 2015 - 2021

9.2.1.5.3.2. Market Forecast, 2022 - 2030

9.2.1.5.4. Middle East and Africa

9.2.1.5.4.1. Market Estimation, 2015 - 2021

9.2.1.5.4.2. Market Forecast, 2022 - 2030

9.2.1.5.5. Latin America

9.2.1.5.5.1. Market Estimation, 2015 - 2021

9.2.1.5.5.2. Market Forecast, 2022 - 2030

9.2.2. Inflammatory Bowel Disease

9.2.2.1. Definition

9.2.2.2. Market Estimation and Penetration, 2015 - 2021

9.2.2.3. Market Forecast, 2022 - 2030

9.2.2.4. Compound Annual Growth Rate (CAGR)

9.2.2.5. Regional Bifurcation

9.2.2.5.1. North America

9.2.2.5.1.1. Market Estimation, 2015 - 2021

9.2.2.5.1.2. Market Forecast, 2022 - 2030

9.2.2.5.2. Europe

9.2.2.5.2.1. Market Estimation, 2015 - 2021

9.2.2.5.2.2. Market Forecast, 2022 - 2030

9.2.2.5.3. Asia Pacific

9.2.2.5.3.1. Market Estimation, 2015 - 2021

9.2.2.5.3.2. Market Forecast, 2022 - 2030

9.2.2.5.4. Middle East and Africa

9.2.2.5.4.1. Market Estimation, 2015 - 2021

9.2.2.5.4.2. Market Forecast, 2022 - 2030

9.2.2.5.5. Latin America

9.2.2.5.5.1. Market Estimation, 2015 - 2021

9.2.2.5.5.2. Market Forecast, 2022 - 2030

9.2.3. Cancer

9.2.3.1. Definition

9.2.3.2. Market Estimation and Penetration, 2015 - 2021

9.2.3.3. Market Forecast, 2022 - 2030

9.2.3.4. Compound Annual Growth Rate (CAGR)

9.2.3.5. Regional Bifurcation

9.2.3.5.1. North America

9.2.3.5.1.1. Market Estimation, 2015 - 2021

9.2.3.5.1.2. Market Forecast, 2022 - 2030

9.2.3.5.2. Europe

9.2.3.5.2.1. Market Estimation, 2015 - 2021

9.2.3.5.2.2. Market Forecast, 2022 - 2030

9.2.3.5.3. Asia Pacific

9.2.3.5.3.1. Market Estimation, 2015 - 2021

9.2.3.5.3.2. Market Forecast, 2022 - 2030

9.2.3.5.4. Middle East and Africa

9.2.3.5.4.1. Market Estimation, 2015 - 2021

9.2.3.5.4.2. Market Forecast, 2022 - 2030

9.2.3.5.5. Latin America

9.2.3.5.5.1. Market Estimation, 2015 - 2021

9.2.3.5.5.2. Market Forecast, 2022 - 2030

9.2.4. Others

9.2.4.1. Definition

9.2.4.2. Market Estimation and Penetration, 2015 - 2021

9.2.4.3. Market Forecast, 2022 - 2030

9.2.4.4. Compound Annual Growth Rate (CAGR)

9.2.4.5. Regional Bifurcation

9.2.4.5.1. North America

9.2.4.5.1.1. Market Estimation, 2015 - 2021

9.2.4.5.1.2. Market Forecast, 2022 - 2030

9.2.4.5.2. Europe

9.2.4.5.2.1. Market Estimation, 2015 - 2021

9.2.4.5.2.2. Market Forecast, 2022 - 2030

9.2.4.5.3. Asia Pacific

9.2.4.5.3.1. Market Estimation, 2015 - 2021

9.2.4.5.3.2. Market Forecast, 2022 - 2030

9.2.4.5.4. Middle East and Africa

9.2.4.5.4.1. Market Estimation, 2015 - 2021

9.2.4.5.4.2. Market Forecast, 2022 - 2030

9.2.4.5.5. Latin America

9.2.4.5.5.1. Market Estimation, 2015 - 2021

9.2.4.5.5.2. Market Forecast, 2022 - 2030

9.3. Key Segment for Channeling Investments

9.3.1. By Application

10. North America Intravenous Iron Drugs Market Analysis and Forecasts, 2022 - 2030

10.1. Overview

10.1.1. North America Intravenous Iron Drugs Market Revenue (US$ Mn)

10.2. North America Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

10.2.1. Iron Dextran

10.2.2. Iron Sucrose

10.2.3. Ferric Carboxymaltose

10.2.4. Others

10.3. North America Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

10.3.1. Chronic Kidney Disease

10.3.2. Inflammatory Bowel Disease

10.3.3. Cancer

10.3.4. Others

10.4. North America Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Country

10.4.1. U.S

10.4.1.1. U.S Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

10.4.1.1.1. Iron Dextran

10.4.1.1.2. Iron Sucrose

10.4.1.1.3. Ferric Carboxymaltose

10.4.1.1.4. Others

10.4.1.2. U.S Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

10.4.1.2.1. Chronic Kidney Disease

10.4.1.2.2. Inflammatory Bowel Disease

10.4.1.2.3. Cancer

10.4.1.2.4. Others

10.4.2. Canada

10.4.2.1. Canada Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

10.4.2.1.1. Iron Dextran

10.4.2.1.2. Iron Sucrose

10.4.2.1.3. Ferric Carboxymaltose

10.4.2.1.4. Others

10.4.2.2. Canada Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

10.4.2.2.1. Chronic Kidney Disease

10.4.2.2.2. Inflammatory Bowel Disease

10.4.2.2.3. Cancer

10.4.2.2.4. Others

10.4.3. Mexico

10.4.3.1. Mexico Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

10.4.3.1.1. Iron Dextran

10.4.3.1.2. Iron Sucrose

10.4.3.1.3. Ferric Carboxymaltose

10.4.3.1.4. Others

10.4.3.2. Mexico Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

10.4.3.2.1. Chronic Kidney Disease

10.4.3.2.2. Inflammatory Bowel Disease

10.4.3.2.3. Cancer

10.4.3.2.4. Others

10.4.4. Rest of North America

10.4.4.1. Rest of North America Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

10.4.4.1.1. Iron Dextran

10.4.4.1.2. Iron Sucrose

10.4.4.1.3. Ferric Carboxymaltose

10.4.4.1.4. Others

10.4.4.2. Rest of North America Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

10.4.4.2.1. Chronic Kidney Disease

10.4.4.2.2. Inflammatory Bowel Disease

10.4.4.2.3. Cancer

10.4.4.2.4. Others

10.5. Key Segment for Channeling Investments

10.5.1. By Country

10.5.2. By Product

10.5.3. By Application

11. Europe Intravenous Iron Drugs Market Analysis and Forecasts, 2022 - 2030

11.1. Overview

11.1.1. Europe Intravenous Iron Drugs Market Revenue (US$ Mn)

11.2. Europe Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

11.2.1. Iron Dextran

11.2.2. Iron Sucrose

11.2.3. Ferric Carboxymaltose

11.2.4. Others

11.3. Europe Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

11.3.1. Chronic Kidney Disease

11.3.2. Inflammatory Bowel Disease

11.3.3. Cancer

11.3.4. Others

11.4. Europe Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Country

11.4.1. France

11.4.1.1. France Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

11.4.1.1.1. Iron Dextran

11.4.1.1.2. Iron Sucrose

11.4.1.1.3. Ferric Carboxymaltose

11.4.1.1.4. Others

11.4.1.2. France Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

11.4.1.2.1. Chronic Kidney Disease

11.4.1.2.2. Inflammatory Bowel Disease

11.4.1.2.3. Cancer

11.4.1.2.4. Others

11.4.2. The UK

11.4.2.1. The UK Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

11.4.2.1.1. Iron Dextran

11.4.2.1.2. Iron Sucrose

11.4.2.1.3. Ferric Carboxymaltose

11.4.2.1.4. Others

11.4.2.2. The UK Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

11.4.2.2.1. Chronic Kidney Disease

11.4.2.2.2. Inflammatory Bowel Disease

11.4.2.2.3. Cancer

11.4.2.2.4. Others

11.4.3. Spain

11.4.3.1. Spain Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

11.4.3.1.1. Iron Dextran

11.4.3.1.2. Iron Sucrose

11.4.3.1.3. Ferric Carboxymaltose

11.4.3.1.4. Others

11.4.3.2. Spain Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

11.4.3.2.1. Chronic Kidney Disease

11.4.3.2.2. Inflammatory Bowel Disease

11.4.3.2.3. Cancer

11.4.3.2.4. Others

11.4.4. Germany

11.4.4.1. Germany Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

11.4.4.1.1. Iron Dextran

11.4.4.1.2. Iron Sucrose

11.4.4.1.3. Ferric Carboxymaltose

11.4.4.1.4. Others

11.4.4.2. Germany Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

11.4.4.2.1. Chronic Kidney Disease

11.4.4.2.2. Inflammatory Bowel Disease

11.4.4.2.3. Cancer

11.4.4.2.4. Others

11.4.5. Italy

11.4.5.1. Italy Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

11.4.5.1.1. Iron Dextran

11.4.5.1.2. Iron Sucrose

11.4.5.1.3. Ferric Carboxymaltose

11.4.5.1.4. Others

11.4.5.2. Italy Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

11.4.5.2.1. Chronic Kidney Disease

11.4.5.2.2. Inflammatory Bowel Disease

11.4.5.2.3. Cancer

11.4.5.2.4. Others

11.4.6. Nordic Countries

11.4.6.1. Nordic Countries Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

11.4.6.1.1. Iron Dextran

11.4.6.1.2. Iron Sucrose

11.4.6.1.3. Ferric Carboxymaltose

11.4.6.1.4. Others

11.4.6.2. Nordic Countries Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

11.4.6.2.1. Chronic Kidney Disease

11.4.6.2.2. Inflammatory Bowel Disease

11.4.6.2.3. Cancer

11.4.6.2.4. Others

11.4.6.3. Nordic Countries Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Country

11.4.6.3.1. Denmark

11.4.6.3.2. Finland

11.4.6.3.3. Iceland

11.4.6.3.4. Sweden

11.4.6.3.5. Norway

11.4.7. Benelux Union

11.4.7.1. Benelux Union Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

11.4.7.1.1. Iron Dextran

11.4.7.1.2. Iron Sucrose

11.4.7.1.3. Ferric Carboxymaltose

11.4.7.1.4. Others

11.4.7.2. Benelux Union Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

11.4.7.2.1. Chronic Kidney Disease

11.4.7.2.2. Inflammatory Bowel Disease

11.4.7.2.3. Cancer

11.4.7.2.4. Others

11.4.7.3. Benelux Union Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Country

11.4.7.3.1. Belgium

11.4.7.3.2. The Netherlands

11.4.7.3.3. Luxembourg

11.4.8. Rest of Europe

11.4.8.1. Rest of Europe Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

11.4.8.1.1. Iron Dextran

11.4.8.1.2. Iron Sucrose

11.4.8.1.3. Ferric Carboxymaltose

11.4.8.1.4. Others

11.4.8.2. Rest of Europe Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

11.4.8.2.1. Chronic Kidney Disease

11.4.8.2.2. Inflammatory Bowel Disease

11.4.8.2.3. Cancer

11.4.8.2.4. Others

11.5. Key Segment for Channeling Investments

11.5.1. By Country

11.5.2. By Product

11.5.3. By Application

12. Asia Pacific Intravenous Iron Drugs Market Analysis and Forecasts, 2022 - 2030

12.1. Overview

12.1.1. Asia Pacific Intravenous Iron Drugs Market Revenue (US$ Mn)

12.2. Asia Pacific Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

12.2.1. Iron Dextran

12.2.2. Iron Sucrose

12.2.3. Ferric Carboxymaltose

12.2.4. Others

12.3. Asia Pacific Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

12.3.1. Chronic Kidney Disease

12.3.2. Inflammatory Bowel Disease

12.3.3. Cancer

12.3.4. Others

12.4. Asia Pacific Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Country

12.4.1. China

12.4.1.1. China Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

12.4.1.1.1. Iron Dextran

12.4.1.1.2. Iron Sucrose

12.4.1.1.3. Ferric Carboxymaltose

12.4.1.1.4. Others

12.4.1.2. China Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

12.4.1.2.1. Chronic Kidney Disease

12.4.1.2.2. Inflammatory Bowel Disease

12.4.1.2.3. Cancer

12.4.1.2.4. Others

12.4.2. Japan

12.4.2.1. Japan Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

12.4.2.1.1. Iron Dextran

12.4.2.1.2. Iron Sucrose

12.4.2.1.3. Ferric Carboxymaltose

12.4.2.1.4. Others

12.4.2.2. Japan Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

12.4.2.2.1. Chronic Kidney Disease

12.4.2.2.2. Inflammatory Bowel Disease

12.4.2.2.3. Cancer

12.4.2.2.4. Others

12.4.3. India

12.4.3.1. India Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

12.4.3.1.1. Iron Dextran

12.4.3.1.2. Iron Sucrose

12.4.3.1.3. Ferric Carboxymaltose

12.4.3.1.4. Others

12.4.3.2. India Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

12.4.3.2.1. Chronic Kidney Disease

12.4.3.2.2. Inflammatory Bowel Disease

12.4.3.2.3. Cancer

12.4.3.2.4. Others

12.4.4. New Zealand

12.4.4.1. New Zealand Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

12.4.4.1.1. Iron Dextran

12.4.4.1.2. Iron Sucrose

12.4.4.1.3. Ferric Carboxymaltose

12.4.4.1.4. Others

12.4.4.2. New Zealand Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

12.4.4.2.1. Chronic Kidney Disease

12.4.4.2.2. Inflammatory Bowel Disease

12.4.4.2.3. Cancer

12.4.4.2.4. Others

12.4.5. Australia

12.4.5.1. Australia Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

12.4.5.1.1. Iron Dextran

12.4.5.1.2. Iron Sucrose

12.4.5.1.3. Ferric Carboxymaltose

12.4.5.1.4. Others

12.4.5.2. Australia Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

12.4.5.2.1. Chronic Kidney Disease

12.4.5.2.2. Inflammatory Bowel Disease

12.4.5.2.3. Cancer

12.4.5.2.4. Others

12.4.6. South Korea

12.4.6.1. South Korea Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

12.4.6.1.1. Iron Dextran

12.4.6.1.2. Iron Sucrose

12.4.6.1.3. Ferric Carboxymaltose

12.4.6.1.4. Others

12.4.6.2. South Korea Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

12.4.6.2.1. Chronic Kidney Disease

12.4.6.2.2. Inflammatory Bowel Disease

12.4.6.2.3. Cancer

12.4.6.2.4. Others

12.4.7. Southeast Asia

12.4.7.1. Southeast Asia Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

12.4.7.1.1. Iron Dextran

12.4.7.1.2. Iron Sucrose

12.4.7.1.3. Ferric Carboxymaltose

12.4.7.1.4. Others

12.4.7.2. Southeast Asia Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

12.4.7.2.1. Chronic Kidney Disease

12.4.7.2.2. Inflammatory Bowel Disease

12.4.7.2.3. Cancer

12.4.7.2.4. Others

12.4.7.3. Southeast Asia Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Country

12.4.7.3.1. Indonesia

12.4.7.3.2. Thailand

12.4.7.3.3. Malaysia

12.4.7.3.4. Singapore

12.4.7.3.5. Rest of Southeast Asia

12.4.8. Rest of Asia Pacific

12.4.8.1. Rest of Asia Pacific Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

12.4.8.1.1. Iron Dextran

12.4.8.1.2. Iron Sucrose

12.4.8.1.3. Ferric Carboxymaltose

12.4.8.1.4. Others

12.4.8.2. Rest of Asia Pacific Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

12.4.8.2.1. Chronic Kidney Disease

12.4.8.2.2. Inflammatory Bowel Disease

12.4.8.2.3. Cancer

12.4.8.2.4. Others

12.5. Key Segment for Channeling Investments

12.5.1. By Country

12.5.2. By Product

12.5.3. By Application

13. Middle East and Africa Intravenous Iron Drugs Market Analysis and Forecasts, 2022 - 2030

13.1. Overview

13.1.1. Middle East and Africa Intravenous Iron Drugs Market Revenue (US$ Mn)

13.2. Middle East and Africa Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

13.2.1. Iron Dextran

13.2.2. Iron Sucrose

13.2.3. Ferric Carboxymaltose

13.2.4. Others

13.3. Middle East and Africa Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

13.3.1. Chronic Kidney Disease

13.3.2. Inflammatory Bowel Disease

13.3.3. Cancer

13.3.4. Others

13.4. Middle East and Africa Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Country

13.4.1. Saudi Arabia

13.4.1.1. Saudi Arabia Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

13.4.1.1.1. Iron Dextran

13.4.1.1.2. Iron Sucrose

13.4.1.1.3. Ferric Carboxymaltose

13.4.1.1.4. Others

13.4.1.2. Saudi Arabia Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

13.4.1.2.1. Chronic Kidney Disease

13.4.1.2.2. Inflammatory Bowel Disease

13.4.1.2.3. Cancer

13.4.1.2.4. Others

13.4.2. UAE

13.4.2.1. UAE Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

13.4.2.1.1. Iron Dextran

13.4.2.1.2. Iron Sucrose

13.4.2.1.3. Ferric Carboxymaltose

13.4.2.1.4. Others

13.4.2.2. UAE Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

13.4.2.2.1. Chronic Kidney Disease

13.4.2.2.2. Inflammatory Bowel Disease

13.4.2.2.3. Cancer

13.4.2.2.4. Others

13.4.3. Egypt

13.4.3.1. Egypt Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

13.4.3.1.1. Iron Dextran

13.4.3.1.2. Iron Sucrose

13.4.3.1.3. Ferric Carboxymaltose

13.4.3.1.4. Others

13.4.3.2. Egypt Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

13.4.3.2.1. Chronic Kidney Disease

13.4.3.2.2. Inflammatory Bowel Disease

13.4.3.2.3. Cancer

13.4.3.2.4. Others

13.4.4. Kuwait

13.4.4.1. Kuwait Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

13.4.4.1.1. Iron Dextran

13.4.4.1.2. Iron Sucrose

13.4.4.1.3. Ferric Carboxymaltose

13.4.4.1.4. Others

13.4.4.2. Kuwait Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

13.4.4.2.1. Chronic Kidney Disease

13.4.4.2.2. Inflammatory Bowel Disease

13.4.4.2.3. Cancer

13.4.4.2.4. Others

13.4.5. South Africa

13.4.5.1. South Africa Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

13.4.5.1.1. Iron Dextran

13.4.5.1.2. Iron Sucrose

13.4.5.1.3. Ferric Carboxymaltose

13.4.5.1.4. Others

13.4.5.2. South Africa Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

13.4.5.2.1. Chronic Kidney Disease

13.4.5.2.2. Inflammatory Bowel Disease

13.4.5.2.3. Cancer

13.4.5.2.4. Others

13.4.6. Rest of Middle East & Africa

13.4.6.1. Rest of Middle East & Africa Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

13.4.6.1.1. Iron Dextran

13.4.6.1.2. Iron Sucrose

13.4.6.1.3. Ferric Carboxymaltose

13.4.6.1.4. Others

13.4.6.2. Rest of Middle East & Africa Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

13.4.6.2.1. Chronic Kidney Disease

13.4.6.2.2. Inflammatory Bowel Disease

13.4.6.2.3. Cancer

13.4.6.2.4. Others

13.5. Key Segment for Channeling Investments

13.5.1. By Country

13.5.2. By Product

13.5.3. By Application

14. Latin America Intravenous Iron Drugs Market Analysis and Forecasts, 2022 - 2030

14.1. Overview

14.1.1. Latin America Intravenous Iron Drugs Market Revenue (US$ Mn)

14.2. Latin America Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

14.2.1. Iron Dextran

14.2.2. Iron Sucrose

14.2.3. Ferric Carboxymaltose

14.2.4. Others

14.3. Latin America Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

14.3.1. Chronic Kidney Disease

14.3.2. Inflammatory Bowel Disease

14.3.3. Cancer

14.3.4. Others

14.4. Latin America Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Country

14.4.1. Brazil

14.4.1.1. Brazil Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

14.4.1.1.1. Iron Dextran

14.4.1.1.2. Iron Sucrose

14.4.1.1.3. Ferric Carboxymaltose

14.4.1.1.4. Others

14.4.1.2. Brazil Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

14.4.1.2.1. Chronic Kidney Disease

14.4.1.2.2. Inflammatory Bowel Disease

14.4.1.2.3. Cancer

14.4.1.2.4. Others

14.4.2. Argentina

14.4.2.1. Argentina Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

14.4.2.1.1. Iron Dextran

14.4.2.1.2. Iron Sucrose

14.4.2.1.3. Ferric Carboxymaltose

14.4.2.1.4. Others

14.4.2.2. Argentina Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

14.4.2.2.1. Chronic Kidney Disease

14.4.2.2.2. Inflammatory Bowel Disease

14.4.2.2.3. Cancer

14.4.2.2.4. Others

14.4.3. Rest of Latin America

14.4.3.1. Rest of Latin America Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Product

14.4.3.1.1. Iron Dextran

14.4.3.1.2. Iron Sucrose

14.4.3.1.3. Ferric Carboxymaltose

14.4.3.1.4. Others

14.4.3.2. Rest of Latin America Intravenous Iron Drugs Market Revenue (US$ Mn) and Forecasts, By Application

14.4.3.2.1. Chronic Kidney Disease

14.4.3.2.2. Inflammatory Bowel Disease

14.4.3.2.3. Cancer

14.4.3.2.4. Others

14.5. Key Segment for Channeling Investments

14.5.1. By Country

14.5.2. By Product

14.5.3. By Application

15. Competitive Benchmarking

15.1. Brand Benchmarking

15.2. Market Share Analysis, 2021

15.3. Global Presence and Growth Strategies

15.3.1. Mergers and Acquisitions

15.3.2. Product Launches

15.3.3. Investments Trends

15.3.4. R&D Initiatives

16. Player Profiles

16.1. AbbVie, Inc.

16.1.1. Company Details

16.1.2. Company Overview

16.1.3. Product Offerings

16.1.4. Key Developments

16.1.5. Financial Analysis

16.1.6. SWOT Analysis

16.1.7. Business Strategies

16.2. Actavis Inc.

16.2.1. Company Details

16.2.2. Company Overview

16.2.3. Product Offerings

16.2.4. Key Developments

16.2.5. Financial Analysis

16.2.6. SWOT Analysis

16.2.7. Business Strategies

16.3. AMAG Pharmaceuticals, Inc.

16.3.1. Company Details

16.3.2. Company Overview

16.3.3. Product Offerings

16.3.4. Key Developments

16.3.5. Financial Analysis

16.3.6. SWOT Analysis

16.3.7. Business Strategies

16.4. American Regent, Inc.

16.4.1. Company Details

16.4.2. Company Overview

16.4.3. Product Offerings

16.4.4. Key Developments

16.4.5. Financial Analysis

16.4.6. SWOT Analysis

16.4.7. Business Strategies

16.5. Daiichi Sankyo Vietnam Company Limited

16.5.1. Company Details

16.5.2. Company Overview

16.5.3. Product Offerings

16.5.4. Key Developments

16.5.5. Financial Analysis

16.5.6. SWOT Analysis

16.5.7. Business Strategies

16.6. Fresenius Medical Care AG & Co. KGaA

16.6.1. Company Details

16.6.2. Company Overview

16.6.3. Product Offerings

16.6.4. Key Developments

16.6.5. Financial Analysis

16.6.6. SWOT Analysis

16.6.7. Business Strategies

16.7. Galenica Ltd.

16.7.1. Company Details

16.7.2. Company Overview

16.7.3. Product Offerings

16.7.4. Key Developments

16.7.5. Financial Analysis

16.7.6. SWOT Analysis

16.7.7. Business Strategies

16.8. Luitpold Pharmaceuticals, Inc.

16.8.1. Company Details

16.8.2. Company Overview

16.8.3. Product Offerings

16.8.4. Key Developments

16.8.5. Financial Analysis

16.8.6. SWOT Analysis

16.8.7. Business Strategies

16.9. Pharmacosmos A/S

16.9.1. Company Details

16.9.2. Company Overview

16.9.3. Product Offerings

16.9.4. Key Developments

16.9.5. Financial Analysis

16.9.6. SWOT Analysis

16.9.7. Business Strategies

16.10. Rockwell Medical Technologies, Inc.

16.10.1. Company Details

16.10.2. Company Overview

16.10.3. Product Offerings

16.10.4. Key Developments

16.10.5. Financial Analysis

16.10.6. SWOT Analysis

16.10.7. Business Strategies

16.11. Sanofi

16.11.1. Company Details

16.11.2. Company Overview

16.11.3. Product Offerings

16.11.4. Key Developments

16.11.5. Financial Analysis

16.11.6. SWOT Analysis

16.11.7. Business Strategies

16.12. Vifor Pharma Ltd.

16.12.1. Company Details

16.12.2. Company Overview

16.12.3. Product Offerings

16.12.4. Key Developments

16.12.5. Financial Analysis

16.12.6. SWOT Analysis

16.12.7. Business Strategies

16.13. Other Market Participants

17. Key Findings

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

**Exclusive for Multi-User and Enterprise User.

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.

Prominent participants in our primary research process include:

Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources: